8-K: Oscar Health Extends CEO Bertolini's Contract, Boosts Compensation

Oscar Health, Inc. has extended CEO Mark T. Bertolini's employment agreement through April 2029, increasing his base salary and target bonus, and granting significant equity awards.

Summary

• Oscar Health, Inc. entered into an amended and restated employment agreement with CEO Mark T. Bertolini, effective December 22, 2025.
• The agreement extends Mr. Bertolini's employment term until April 1, 2029, with automatic one-year renewals thereafter.
• His annual base salary is set at $1,300,000.
• Commencing in calendar year 2026, his target annual bonus will increase to 150% of his annual base salary.
• In the first quarter of 2026, Mr. Bertolini will receive two restricted stock unit (RSU) awards totaling $45,000,000 in value, split equally between time-based and performance-based awards.
• The agreement includes enhanced severance provisions, offering a 1.5x cash severance multiplier and 18 months of company-subsidized healthcare coverage upon a qualifying termination.

Sentiment

Score: 7

Explanation: The filing reflects stability in leadership and a strong commitment to the current CEO, which is generally positive. The compensation package is substantial but structured to incentivize performance, balancing shareholder interests with executive retention. No negative operational or financial news is present.

Positives

• Secures the continued leadership of CEO Mark T. Bertolini through April 1, 2029, providing stability for the company.
• The compensation package, including a $1,300,000 annual base salary, a 150% target annual bonus, and $45,000,000 in equity awards, is designed to incentivize long-term performance.
• The equity awards are split between time-based (50%) and performance-based (50%) components, aligning executive compensation with company performance and shareholder interests.
• Enhanced severance terms provide a safety net for the CEO, which can be attractive for retaining top talent.

Negatives

• The significant increase in compensation, including a $45,000,000 equity grant and a higher target bonus, represents a substantial expense for the company.
• The enhanced severance package, including a 1.5x cash severance multiplier and 18 months of healthcare coverage, could result in considerable payouts in the event of a qualifying termination.
• Mr. Bertolini is not expected to receive additional long-term incentive or equity-based awards prior to calendar year 2029, which could be seen as a limitation on future incentive opportunities, though the current grant is substantial.

Risks

• The performance-based equity awards are subject to the achievement of specified performance goals, meaning the full value may not be realized if targets are not met.
• The company faces potential significant severance costs if Mr. Bertolini's employment is terminated without cause or for good reason.
• A change in control event could trigger accelerated vesting of equity awards, potentially leading to a large payout to the CEO regardless of long-term performance post-acquisition.

Future Outlook

The filing indicates a commitment to Mark T. Bertolini's leadership through at least April 2029, suggesting stability in executive management. The structure of the equity awards, particularly the performance-based component, ties future executive compensation to the achievement of specified company performance goals.

Industry Context

Executive compensation packages, particularly those involving significant equity grants and performance incentives, are common in the healthcare technology sector to attract and retain experienced leadership. The extension of a CEO's contract often signals confidence in the current strategic direction and leadership, which is a positive signal in a competitive and evolving industry.

Comparison to Industry Standards

• The base salary of $1,300,000 for a CEO of a publicly traded healthcare technology company like Oscar Health is generally within the competitive range for companies of similar size and market capitalization, though specific comparisons would require detailed peer group analysis.
• A target annual bonus of 150% of base salary is a robust incentive, aligning with practices at many growth-oriented tech and healthcare firms.
• The $45,000,000 equity grant, split between time-based and performance-based RSUs, is a substantial award, reflecting a long-term retention and performance incentive strategy often seen in high-growth or turnaround situations. For example, CEOs at companies like Teladoc Health or Amwell might receive significant equity, though the specific amounts vary widely based on company stage, performance, and market conditions.
• Severance provisions, including a 1.5x cash multiplier and 18 months of healthcare, are standard, if on the more generous side, for C-suite executives in the U.S., comparable to agreements at companies such as Humana or Cigna.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Provides stability in leadership, but also entails significant executive compensation costs. The performance-based equity aims to align CEO interests with shareholder value creation.
• Employees: May signal stability at the top, potentially boosting morale or confidence in the company's direction.
• Customers: Indirect impact through continued strategic direction under existing leadership.

Next Steps

• Granting of the $45,000,000 restricted stock unit (RSU) awards to Mr. Bertolini in the first quarter of 2026.
• Commencement of the increased target annual bonus for Mr. Bertolini in calendar year 2026.
• Continued employment of Mr. Bertolini as CEO until at least April 1, 2029, subject to terms.

Key Dates

Recommendation

The filing primarily concerns executive compensation and leadership stability, which are important but typically do not fundamentally alter the investment thesis for a company unless there are unexpected changes in leadership or excessively egregious compensation terms. The extension of the CEO's contract provides continuity, which is generally positive, but the substantial compensation package is a cost. Given this is an expected renewal, it's unlikely to cause a dramatic shift in valuation, hence a 'hold' recommendation, pending broader financial performance and strategic updates.

Keywords

Oscar Health, Mark T. Bertolini, CEO employment agreement, executive compensation, restricted stock units, performance stock units, severance package, corporate governance, healthcare technology, OSCR